doi: 10.3389/fendo.2026.1813721 Received 19 February 2026 Revised 30 April 2026 Accepted 06 May 2026 Published 25 May 2026 Volume 17 - 2026 Edited by Martine Culty, University of Southern California, United States Reviewed by Penglin Zou, Shanghai First Peoples Hospital, China Halil brahim velik, Kutahya Health Sciences University, Trkiye Updates Copyright 2026 Xu and Yu
Then injections only every 12 weeks
10.1016/j.bbrc.2019.01.103 Summary Keywords heart failure, cognitive impairment, type 2 diabetes, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors Citation Riemma MA, Mele E, Donniacuo M, Telesca M, Bellocchio G, Castaldo G, Rossi F, De Angelis A, Cappetta D, Urbanek K and Berrino L (2024) Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
Level of evidence There are no RCTs specifically targeting this topic